Teva Pharma SVP & General Counsel Dov Bergwerk Files Form 144 to Sell $1.1M in Shares

Executive Summary

On November 4, 2026, Bergwerk Dov, Senior Vice President, General Counsel, and Corporate Secretary of Teva Pharmaceutical Industries Ltd ($TEVA), filed a Form 144 notifying the proposed sale of 26,260 ordinary shares with an aggregate market value of approximately $1,095,567.20 ($41.72 per share).

Transaction Breakdown

• Security: Ordinary Shares
• Shares Proposed for Sale: 26,260
• Aggregate Market Value: $1,095,567.20
• Indicative Price Per Share: $41.72
• Nature of Acquisition: Acquired on November 4, 2026, via stock option exercise and simultaneous sale.
• Broker: Citigroup Global Markets, Inc.
• Approximate Sale Date: November 4, 2026

Market & Governance Implications

• Transaction Nature: The transaction represents an exercise and immediate sale of employee stock options paid in cash.
• Significance: Classified as Low trading significance given that option exercise-and-sell events are routine liquidity and compensation-realization transactions rather than open-market discretionary divestitures of long-held equity.